• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

May 22, 2014

View Archived Issues

Chimerix raises $103M for brincidofovir push; potential use widens

More than half the gross proceeds of Chimerix Inc.'s $103.8 million from a public offering will go toward advancing the oral nucleotide analogue lipid-conjugate drug brincidofovir, the company said in its 424B5 filing with the SEC, pricing 7.3 million shares at $14.22 each in a deal set to close next week. Read More

Voltarra seeks 'lightning' strike with zoledronic acid derivative in knee OA

Launched last year with a portfolio of early stage small molecules and late-stage clinical assets assembled through a pair of acquisitions, Voltarra Pharmaceuticals Inc. has moved like lightning – a strategy underpinning the company's name – into phase III trials for its lead candidate. Read More

Lysogene raises $23M for Sanfilippo syndrome A gene therapy

Lysogene SAS raised €16.5 million (US$22.6 million) in a series A round to continue its clinical development of SAF-301, a gene therapy treatment for Sanfilippo syndrome type A, a rare neurodegenerative disorder arising from impaired breakdown of the cell surface and extracellular matrix component heparan sulfate. Read More

States signal on 'right to try': Washington, we have a problem

Sending a clear signal to Washington, Louisiana is poised to become the second state to enact a law recognizing the right of terminally ill patients, who have run out of options, to try investigational drugs and devices. Read More

Recent start-up Cour lands former Pfizer R&D chief as chairman

Cour Pharmaceutical Development Co. Inc., a small company developing nanotechnology-based immunotherapies for acute inflammation and autoimmune disease, has appointed Pfizer R&D veteran Catherine Mackey as chairman of its board. Read More

Other news to note

Inhibikase Therapeutics Inc., of Atlanta, said it received FDA orphan drug designation for imatinib to treat progressive multifocal leukoencephalopathy (PML), a rare side effect of small-molecule and antibody drugs given to patients with autoimmune diseases such as arthritis and multiple sclerosis and a disease that occurs in 1 percent to 3 percent of clinical AIDS patients. Read More

Stock movers

Read More

In the clinic

Amgen, of Thousand Oaks, Calif., said The New England Journal of Medicine published results from a phase I study suggesting that inhibiting thymic stromal lymphopoietin (TSLP) could benefit the treatment of asthma. Read More

Pharma: Other news to note

Daiichi Sankyo Co. Ltd., of Tokyo, began a three-year research project with Sanford-Burnham Medical Research Institute, of La Jolla, Calif., to investigate cardiovascular-metabolic diseases. Read More

Pharma: In the clinic

Boehringer Ingelheim GmbH, of Boehringer, Germany, presented results from the phase III VIVACITO study at the American Thoracic Society meeting in San Diego, showing that the fixed-dose combination of tiotropium and olodaterol, delivered via the Respimat inhaler, demonstrated a statistically significant improvement over both monotherapy treatment (p < 0.0001) and placebo (p < 0.0001) in the primary endpoint, defined as the forced expiratory volume in one second. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 23, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 23, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 17, 2025
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BIO2025: John Crowley and Martin Makary

    BIO 2025: Makary lays out FDA’s path, launches pilot review program

    BioWorld
    On the same day that FDA Commissioner Martin Makary spoke in a fireside chat during the 2025 Biotechnology Innovation Organization’s International Convention, the...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe